Understanding Cardiometabolic Health & Its Importance for Your Long-Term Wellbeing

Key Biomarkers: Understanding Your Cardiometabolic Profile

Comprehensive cardiometabolic assessment requires evaluation across multiple domains:

Cholesterol and Lipid Markers

Standard Lipid Panel:

– Total Cholesterol: The sum of all cholesterol in your blood

– LDL-C (Low-Density Lipoprotein Cholesterol): Often called “bad” cholesterol, elevated levels promote arterial plaque formation

– HDL-C (High-Density Lipoprotein Cholesterol): “Good” cholesterol that helps remove excess cholesterol from arteries

– Triglycerides: A type of fat; elevated levels (≥150 mg/dL) increase cardiovascular risk and are a component of metabolic syndrome

Advanced Lipid Markers:

– ApoB (Apolipoprotein B): The primary protein on LDL and other atherogenic particles. Each atherogenic particle contains one ApoB molecule, making this a direct measure of particle number[13][14]

– ApoA1 (Apolipoprotein A-I): The main protein on HDL particles

– ApoB/ApoA1 Ratio: Some evidence suggests this ratio may identify cardiovascular risk earlier than standard lipids, particularly in younger individuals[13][14][15]

Clinical Context: While ApoB and ApoA1 are strong predictors of cardiovascular events, large-scale studies show that when total cholesterol and HDL-C are already measured, adding apolipoproteins provides only minimal additional predictive value for most patients.[16][17] These advanced markers may be most useful in specific situations, such as discordant risk assessments or familial lipid disorders.

Blood Glucose Markers

– Fasting Glucose: Normal is 100 mg/dL; 100-125 mg/dL indicates prediabetes; ≥126 mg/dL suggests diabetes[3]

– HbA1c (Hemoglobin A1c): Reflects average blood glucose over approximately 3 months. Normal is 5.7%; 5.7-6.4% indicates prediabetes; ≥6.5% suggests diabetes[3]

– Fasting Insulin: Elevated levels may indicate insulin resistance, often present years before blood glucose becomes abnormal

Inflammation Markers

High-Sensitivity C-Reactive Protein (hsCRP): This marker of systemic inflammation has emerged as a clinically actionable biomarker with predictive value comparable to LDL cholesterol and blood pressure.[7][18]

– 1 mg/L: Lower cardiovascular risk

– 1-3 mg/L: Average risk

– >3 mg/L: Higher risk

– >10 mg/L: May indicate acute infection; should be repeated in 2-3 weeks[7]

The 2025 ACC Scientific Statement recommends universal hsCRP screening in both primary and secondary prevention.[7] A 30-year study in women found that hsCRP provided greater risk stratification than LDL cholesterol or lipoprotein(a).[7] Importantly, chronic inflammation is modifiable through lifestyle interventions including weight loss, exercise, smoking cessation, and healthy diet.[7][19]

Adiposity Measures

– Body Mass Index (BMI): Optimal 25 kg/m²; overweight 25-30 kg/m²; obesity ≥30 kg/m²

– Waist Circumference: Reflects visceral (abdominal) fat. Elevated risk: >102 cm (40 inches) in men, >88 cm (35 inches) in women[3]

Important Note: Not all individuals with elevated BMI have poor metabolic health (“metabolically healthy obesity”), and some lean individuals have metabolic dysfunction (“metabolically unhealthy lean”).[6] Waist circumference often better reflects metabolic risk than BMI alone.

Blood Pressure

– Optimal: 120/80 mmHg without medication

– Elevated: 120-129/80 mmHg

– Hypertension: ≥130/80 mmHg or on blood pressure medication[3]

Liver and Kidney Function

– ALT (Alanine Aminotransferase): Elevated levels may indicate metabolic-associated fatty liver disease, increasingly recognized as part of the cardiometabolic spectrum[2]

– Creatinine and eGFR (Estimated Glomerular Filtration Rate): Assess kidney function, critical given the kidney’s role in CKM syndrome[1][2]

Additional Markers

– Cortisol: The stress hormone influences blood pressure, glucose metabolism, and fat distribution

– TSH (Thyroid-Stimulating Hormone): Thyroid dysfunction affects metabolism, heart rate, and cholesterol levels

– Homocysteine: Elevated levels are associated with increased cardiovascular risk, though routine screening is not currently recommended[5]

Why Monitoring Cardiometabolic Biomarkers Matters

Early Detection: Metabolic abnormalities often precede clinical disease by decades. For example, elevated hsCRP can be detected 20 years before cardiovascular events occur.[13] Insulin resistance may develop 10-15 years before diabetes diagnosis.

Personalized Risk Assessment: The combination of multiple biomarkers provides superior risk stratification. Individuals with elevated hsCRP, LDL cholesterol, and lipoprotein(a) experience cardiovascular events several years earlier than those with normal levels.[7]

Treatment Guidance: Biomarker patterns inform therapeutic decisions. For instance, the JUPITER trial demonstrated that individuals with normal LDL cholesterol (130 mg/dL) but elevated hsCRP (≥2 mg/L) experienced a 47% reduction in cardiovascular events with statin therapy.[7][19]

Monitoring Progress: Serial measurements track response to lifestyle and pharmacological interventions, enabling treatment optimization.

Evidence-Based Lifestyle Interventions for Cardiometabolic Health

The American Heart Association’s “Life’s Essential 8” provides a comprehensive framework for optimizing cardiometabolic health, encompassing diet, physical activity, nicotine exposure, sleep, body weight, blood lipids, blood glucose, and blood pressure.[1][20]

Dietary Approaches

Mediterranean Diet: The most extensively studied dietary pattern for cardiometabolic health, characterized by high intake of vegetables, fruits, whole grains, legumes, nuts, olive oil, and fish, with moderate wine consumption and limited red meat.[6][21][22] This pattern reduces metabolic syndrome risk, inflammation, and hepatic steatosis while improving lipid profiles and insulin sensitivity.

Plant-Based Diets: Emphasizing whole plant foods while minimizing or eliminating animal products improves multiple cardiometabolic risk factors.[21][22]

Final Thoughts

Cardiometabolic health is no longer a future concern—it is a present-day determinant of longevity, cognitive resilience, and overall quality of life. The modern CKM framework makes it clear that cardiovascular disease, diabetes, chronic kidney disease, and metabolic dysfunction share common upstream drivers long before clinical disease is diagnosed. By the time symptoms appear, pathology is often well established.

A proactive, biomarker-driven approach allows these risks to be identified early—often decades earlier—when intervention is most effective. Advanced lipid testing, inflammatory markers such as hsCRP, insulin and glucose dynamics, body composition metrics, and liver and kidney function together provide a far more accurate picture of cardiometabolic risk than traditional screening alone. Importantly, these markers are dynamic and modifiable, meaning targeted lifestyle, nutritional, and medical strategies can meaningfully alter disease trajectory.

At Intercoastal Health, cardiometabolic risk is not addressed in isolation. Instead, it is evaluated within a comprehensive functional medicine framework that seeks to identify root causes, personalize interventions, and monitor progress over time. This approach supports not only disease prevention, but long-term metabolic resilience and healthy aging.

Intercoastal Health provides Testosterone Replacement Therapy (TRT) & Hormone Replacement Therapy , Enclomiphene Citrate Therapy in Jacksonville, FL, delivered through a comprehensive, multimodal approach to healthspan optimization. Our care model integrates evidence-based hormone management with advanced metabolic, lifestyle, and preventive strategies to support long-term vitality and resilience.

In addition, we offer targeted peptide therapies designed to support recovery, tissue repair, and physiological optimization, including BPC-157, Pentadeca Arginate, and Sermorelin—each incorporated into individualized treatment plans based on clinical evaluation and goals.